PAR 41.5% 46.0¢ paradigm biopharmaceuticals limited..

The competition and their side effects, page-4

  1. 33 Posts.
    lightbulb Created with Sketch. 37
    Your top-level comparison certainly paints a good picture for PPS. But I do think you’re being a bit too kind about opioids – even if you have described them negatively.

    This is a quote from the RACGP (Royal Australian College of General Practice) - on the use of opioids in chronic non-cancer pain in 2013. A bit old – but Since then concerns have raised even more - as has prescribing of drugs like Targin, Oxycontin, Norspan etc which have gone through the roof. (I’ve added bold for emphasis)

    "For chronic non-cancer pain, the evidence base for the long-term use of opiates is mediocre, with weak support for minimal improvements in pain measures and little or no evidence for functional restoration. Much research and professional education in this field has been underwritten by commercial interests. Escalating the prescribing of opioids has been repeatedly linked to a myriad of individual and public harms, including overdose deaths. Many patients on long-term opioids may never be able to taper off them, despite their associated toxicities and lack of efficacy."

    (See https://www.racgp.org.au/afp/2013/march/opioid-use-part-1/)

    If PPS can’t beat opioids then who can?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
46.0¢
Change
0.135(41.5%)
Mkt cap ! $82.30M
Open High Low Value Volume
34.0¢ 49.5¢ 34.0¢ $3.506M 8.474M

Buyers (Bids)

No. Vol. Price($)
1 10000 45.5¢
 

Sellers (Offers)

Price($) Vol. No.
46.0¢ 147167 1
View Market Depth
Last trade - 16.10pm 25/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.